Expertise in
6
conditions

Dr. Rui Li

Hematology | Oncology
4805 Northeast Glisan Street, Suite 11N-1, 
Portland, OR 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
6
conditions
4805 Northeast Glisan Street, Suite 11N-1, 
Portland, OR 

Overview

Rui Li is a Hematologist and an Oncologist practicing medicine in Portland, Oregon.

Dr. Li is highly rated in 6 conditions, according to our data. Her clinical expertise encompasses Cervical Cancer, Large-Cell Immunoblastic Lymphoma, Myelodysplastic Syndrome (MDS), and Diffuse Large B-Cell Lymphoma (DLBCL).

She is actively involved in clinical research, co-authoring 2 peer reviewed articles and participating in 20 clinical trials. Dr. Li is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in OR

Hospital Affiliations

Ohsu Hospital And Clinics
Providence Milwaukie Hospital
Providence Willamette Falls Medical Center
Providence Portland Medical Center
Providence St Vincent Medical Center

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BridgeSpan
  • EPO
  • HMO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Moda Health
  • EPO
  • PPO
Prominence Health
  • EPO
  • PPO
Regence
  • EPO
  • PPO
Trillium
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

4805 Northeast Glisan Street, Suite 11N-1, Portland, OR 97213

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

20 Clinical Trials

Neoadjuvant Immunoradiotherapy: Head & Neck Cancer (NIRT-HNC)
Neoadjuvant Immunoradiotherapy: Head & Neck Cancer (NIRT-HNC)
Enrollment Status: Active_not_recruiting
Publish Date: July 23, 2026
Intervention Type: Procedure, Drug, Radiation
Study Drug: Nivolumab
Study Phase: Phase 1/Phase 2
Phase II Randomized Study of High Dose Interleukin-2 Versus Stereotactic Body Radiation (SBRT) and High Dose Interleukin-2 (IL-2) in Patients With Metastatic Renal Cancer
Phase II Randomized Study of High Dose Interleukin-2 Versus Stereotactic Body Radiation (SBRT) and High Dose Interleukin-2 (IL-2) in Patients With Metastatic Renal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 23, 2026
Intervention Type: Radiation, Biological
Study Drug: High Dose IL-2
Study Phase: Phase 2
Phase Ib Study of a Monoclonal Antibody to OX40 (MEDI0562) Administered Prior to Surgical Resection in Patients With Head and Neck Squamous Cell Carcinoma or Melanoma
Phase Ib Study of a Monoclonal Antibody to OX40 (MEDI0562) Administered Prior to Surgical Resection in Patients With Head and Neck Squamous Cell Carcinoma or Melanoma
Enrollment Status: Completed
Publish Date: May 22, 2026
Intervention Type: Drug
Study Drug: MEDI0562
Study Phase: Phase 1
A Phase 2 Study to Assess the Safety and Efficacy of Scalp Cooling Using PenguinTM Cold Caps for the Prevention or Reduction of Chemotherapy-induced Alopecia in Stage I-III Breast Cancer
A Phase 2 Study to Assess the Safety and Efficacy of Scalp Cooling Using PenguinTM Cold Caps for the Prevention or Reduction of Chemotherapy-induced Alopecia in Stage I-III Breast Cancer
Enrollment Status: Completed
Publish Date: April 28, 2026
Intervention Type: Device
Study Phase: Not Applicable
Intratumoral Ipilimumab in Head and Neck Cancer
Intratumoral Ipilimumab in Head and Neck Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 24, 2026
Intervention Type: Drug
Study Drug: Ipilimumab
Study Phase: Phase 1
A Pilot and Phase II Study to Assess the Safety, Tolerability and Efficacy of Pembrolizumab Plus Chemotherapy in Metastatic Triple Negative Breast Cancer Patients
A Pilot and Phase II Study to Assess the Safety, Tolerability and Efficacy of Pembrolizumab Plus Chemotherapy in Metastatic Triple Negative Breast Cancer Patients
Enrollment Status: Active_not_recruiting
Publish Date: April 24, 2026
Intervention Type: Drug
Study Drugs: Pembrolizumab, Paclitaxel, Capecitabine
Study Phase: Phase 1/Phase 2
Phase II Randomized Study of High Dose Interleukin-2 Versus Stereotactic Body Radiation (SBRT) and High Dose Interleukin-2 (IL-2) in Patients With Metastatic Melanoma
Phase II Randomized Study of High Dose Interleukin-2 Versus Stereotactic Body Radiation (SBRT) and High Dose Interleukin-2 (IL-2) in Patients With Metastatic Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: April 24, 2026
Intervention Type: Drug, Other
Study Drug: High-dose IL-2
Study Phase: Phase 2
Phase II Study of TGFβ Type I Receptor Inhibitor LY2157299 With Neoadjuvant Chemoradiation in Patients With Locally Advanced Rectal Adenocarcinoma
Phase II Study of TGFβ Type I Receptor Inhibitor LY2157299 With Neoadjuvant Chemoradiation in Patients With Locally Advanced Rectal Adenocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug, Procedure
Study Drugs: LY2157299, Capecitabine, Fluorouracil
Study Phase: Phase 2
A Phase II Study of Nivolumab Combined With Bicalutamide and Ipilimumab in Metastatic HER2-negative Breast Cancer
A Phase II Study of Nivolumab Combined With Bicalutamide and Ipilimumab in Metastatic HER2-negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab, Bicalutamide
Study Phase: Phase 2
Phase Ib Study of Neoadjuvant DPX-Survivac, Aromatase Inhibition, and With/Without Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer
Phase Ib Study of Neoadjuvant DPX-Survivac, Aromatase Inhibition, and With/Without Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug, Radiation, Biological
Study Drugs: DPX-Survivac, Letrozole, Cyclophosphamide
Study Phase: Phase 1
View 9 Less Clinical Trials

2 Total Publications

Quantification of Xanthone and Anthocyanin in Mangosteen Peel by UPLC-MS/MS and Preparation of Nanoemulsions for Studying Their Inhibition Effects on Liver Cancer Cells.
Quantification of Xanthone and Anthocyanin in Mangosteen Peel by UPLC-MS/MS and Preparation of Nanoemulsions for Studying Their Inhibition Effects on Liver Cancer Cells.
Journal: International journal of molecular sciences
Published: January 19, 2023
Similar Doctors
Expertise in
5
conditions
Dr. Michael P. Recht
Hematology | Oncology
Expertise in
5
conditions
Dr. Michael P. Recht
Hematology | Oncology
Referral may be required

Doernbecher Children's Hospital

700 SW Campus Dr, 
Portland, OR 
 (4.2 miles away)
503-494-8716
Languages Spoken:
English
See accepted insurances

Michael Recht is a Hematologist and an Oncologist practicing medicine in Portland, Oregon. Dr. Recht is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Hemophilia A, Blood Clots, Hemophilia B, Glanzmann Thrombasthenia, and Endoscopy.

Expertise in
8
conditions
Dr. Hagen F. Kennecke
Hematology | Oncology
Expertise in
8
conditions
Dr. Hagen F. Kennecke
Hematology | Oncology
Referral may be required

Providence Cancer Institute Franz Clinic

4805 NE Glisan St Ste 11N-1, 
Portland, OR 
 (0.9 miles away)
503-215-5696
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Hagen Kennecke is a Hematologist and an Oncologist practicing medicine in Portland, Oregon. Dr. Kennecke is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET), and Carcinoid Syndrome. Dr. Kennecke is currently accepting new patients.

Expertise in
4
conditions
Dr. Stephen S. Roberts
Hematology | Oncology
Expertise in
4
conditions
Dr. Stephen S. Roberts
Hematology | Oncology
Referral may be required

OHSU Hospital

3181 SW Sam Jackson Park Rd, 
Portland, OR 
 (4.1 miles away)
503-494-1543
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Stephen Roberts is a Hematologist and an Oncologist practicing medicine in Portland, Oregon. Dr. Roberts is highly rated in 4 conditions, according to our data. His clinical expertise encompasses Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Gliomatosis Cerebri, and Hereditary Neuroblastoma. Dr. Roberts is currently accepting new patients.

Frequently Asked Questions about Dr. Rui Li

How do I make an appointment with Dr. Rui Li?

You can book an appointment with Dr. Rui Li by calling their office at 503-215-5696. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Rui Li a top-rated expert for Cervical Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Rui Li is classified as an Distinguished expert for Cervical Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Rui Li specialize in?

While Dr. Rui Li is a Hematology, they have specific expertise in Cervical Cancer, Large-Cell Immunoblastic Lymphoma, and Myelodysplastic Syndrome (MDS). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Rui Li participate in research or clinical trials?

Yes. Dr. Rui Li has published 2 articles and abstracts on conditions like Cervical Cancer. You can view a list of Dr. Rui Li's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Rui Li accept my insurance?

Dr. Rui Li accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 503-215-5696 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Li's expertise for a condition
ConditionClose
    View All 86 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile